 Billing and Coding Guidelines:

Contractor Name
Wisconsin Physicians Service Insurance Corporation

Title
GSURG-052 Application of Bioengineered Skin Substitutes

LCD Database ID Number
L30135

Effective Date
08/16/2009

Revision Effective Date
01/01/2012

AMA CPT/ ADA CDT Copyright Statement
CPT codes, descriptions and other data only are copyright 2010 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. © 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply

CMS National Coverage
Title XVIII of the Social Security Act section 1862 (a)(1)(A). This section allows coverage and payment of those services that are considered to be medically reasonable and necessary.

Benefits Manual section on surgical dressings (Ch.15 sect.100)

Coding Guidelines
Application of Bioengineered Skin Substitutes and Skin Grafting is performed on ulcers that are free of infection and underlying osteomyelitis.

These guidelines include both the care of the wounds prior to the application of the skin substitute.

Skin Replacement (CPT codes 15002 - 15005)
1. Per the definitions and the guidelines in CPT Code Book codes CPT codes 15002/15005 are not appropriate codes to use when performing a non-surgical application of a skin substitute.
2. CPT code 15002/15005 are only appropriately used in place of service inpatient hospital, outpatient hospital or ambulatory surgical center with regional or general anesthesia to resurface an area damaged by burns, traumatic injury or surgery. An operative report is required and must be available upon request.

Coding Guidelines
1. Active wound care, performed with minimal anesthesia is billed with either CPT code 97597 or 97598.
2. Significant debridement of a wound, performed before the application of a topical or local anesthesia is billed with CPT codes 11042 – 11047.
3. CPT codes 11043, 11046, 11044, and 11047 are usually appropriately billed in place of service inpatient hospital, outpatient hospital or ambulatory care center (ASC). Billing of these codes in
another place of service is most likely a billing error and thus the service will be denied. If a provider feels that CPT 11043, 11046, 11044, or 11047 were actually performed in another place of service, a review of the denied claim should be requested and documentation, including an operative report, should be submitted.

4. Use CPT codes 15271 - 15278 for the surgical preparation or creation of recipient site for the tissue skin graft.

5. To bill for an Apligraf® (HCPCS Q4101) package (equal to 44-sq. cm.). If more than 44-sq. cm. is needed for additional grafting, bill according to the number of single units of Apligraf®, indicate Apligraf® in Item 19 of the CMS 1500 Claim Form or the Comment Field for EMC claims.

6. Payment for Apligraf® for any single ulcer will not be made for re-treatment within 1 year after initial treatment.

7. Dermagraft® (HCPCS Q4106) is supplied frozen in a clear bag containing one piece of approximately 2 in. x 3 in. (5 cm. x 7.5 cm.) for a single use application.

8. Claims submitted for skin substitutes should bill the actual size used rounding up to the next whole number.

9. When submitting a claim for skin substitutes, providers are required to accept assignment for this service. Providers, who do not accept assignment, should bill the skin product on a separate claim from other services performed on the same day.

10. Products such as Integra are classified by the Federal Drug Administration as wound dressing and are thus not payable separately by Medicare Part B for outpatient services. The application of Integra or similar FDA classified products may be payable as an inpatient for its FDA approved indication for the treatment of life-threatening full-thickness or deep partial-thickness burns.

11. For services on or after November 1, 2007, the Oasis® Wound Matrix is covered and separately payable when used according to FDA labeled indications and in accordance with accepted standards of medical/surgical practice.

12. The application of Oasis® Wound Matrix (CPT code 15271 - 15278) will be paid no more frequently than at 90-day intervals. Though payment for the product is allowed appropriate to the clinical considerations, it is inappropriate to bill application codes multiple times within a 90-day period using such modifiers as 58, suggesting a staged procedure.

13. Payable places of service for TheraSkin® (HCPCS code Q4121) if billed by the facility: outpatient hospital, (22), emergency room (23), and ambulatory surgical center (24).

14. Payable places of service for TheraSkin® (HCPCS code Q4121) if billed by the physician or non-physician practitioner: office (11), urgent care facility (20), and independent clinic (49).

Documentation Requirements

1. The medical record must clearly show that the criteria listed in LCD GSURG-052 under “Indications and Limitation of Coverage and/or Medical Necessity” have been met.

2. The medical record must clearly document that conservative pre-treatment wound management has been tried and failed to induce healing.

3. There must be a documented plan of care with documented goals and documented provider follow-up present in the patient's medical record. Wound healing must be a medically reasonable expectation based on the clinical circumstances documented.

4. Documentation of the progress of the wound’s response to treatment must be made for each service billed. At a minimum this must include current wound size, wound depth, presence and extent of or absence of obvious signs of infection, presence and extent of or absence of necrotic, devitalized or non-viable tissue, or other material in the wound that is expected to inhibit healing or promote adjacent tissue breakdown.

5. When debridements are performed, the debridement procedure notes must document tissue removal (i.e. skin, full or partial thickness; subcutaneous tissue; muscle; and/or bone), the method used to debride (i.e., hydrostatic versus sharp versus abrasion methods), and the character of the
wound (including dimensions, description of necrotic material present, description of tissue removed, degree of epithelialization, etc.) before and after debridement.

6. Consistent with FDA product labeling, since the use of these products is limited to clean wounds, a description of wound must be documented in the medical records.

7. When, the documentation does not meet the criteria for the service rendered or the documentation does not establish the medical necessity for the services, such services will be denied as not reasonable and necessary under Section 1862(a)(1) of the Social Security Act.

Part A  
**Correct Reporting of Drugs and Biologicals When Used As Implantable Devices**

When billing for biologicals where the HCPCS code describes a product that is solely surgically implanted or inserted, whether the HCPCS code is identified as having pass-through status or not, hospitals are to report the appropriate HCPCS code for the product. In circumstances where the implanted biological has pass-through status, a separate payment for the biological is made. In circumstances where the implanted biological does not have pass-through status, the OPPS payment for the biological is packaged into the payment for the associated procedure. When billing for biologicals where the HCPCS code describes a product that may either be surgically implanted or inserted or otherwise applied in the care of a patient, hospitals should not separately report the biological HCPCS code, with the exception of biologicals with pass-through status, when using these items as implantable devices (including as a scaffold or an alternative to human or nonhuman connective tissue or mesh used in a graft) during surgical procedures. Under the OPPS, hospitals are provided a packaged APC payment for surgical procedures that includes the cost of supportive items, including implantable devices without pass-through status. When using biologicals during surgical procedures as implantable devices, hospitals may include the charges for these items in their charge for the procedure, report the charge on an uncoded revenue center line, or report the charge under a device HCPCS code (if one exists) so these costs would appropriately contribute to the future median setting for the associated surgical procedure.

Note: This information does not apply to skin substitutes.

**Date Published/Website:**
01/01/2012, 12/01/2011, 01/01/2011, 12/01/2010; 07/01/2009

**Revision History/Explanation:**
01/01/2012, Added TheraSkin®, 2012 CPT code update, Per 2012 HCPCS update, added CPT codes 15271-15278, deleted CPT codes 15340-15431 and G0440-G0441, removed references to codes; 12/01/2011, Corrected by adding CPT codes 11043 and 11046 so that statement three now reads: 3. CPT codes 11043, 11046, 11044, and 11047 are usually appropriately billed in place of service inpatient hospital, outpatient hospital or ambulatory care center (ASC). Billing of these codes in another place of service is most likely a billing error and thus the service will be denied. If a provider feels that CPT 11043, 11046, 11044, or 11047 were actually performed in another place of service, a review of the denied claim should be requested and documentation, including an operative report, should be submitted.; 01/01/2011, CPT code update 2011; 12/01/2010, two, added information regarding Q4110 Skin substitute, PriMatrix, use in POS office, per FDA, CPT Code 15360 and 15361 not covered for Dermagraft; 12/01/2009

**Notes**
* - An asterisk indicates a revision to that section of the policy.
NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See §1869(f)(1)(A)(i) of the Social Security Act.